Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C
The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Study of Silymarin for Improving Hepatitis C|
- Serum aminotransferases (ALT, AST) [ Time Frame: at six months after admission ] [ Designated as safety issue: Yes ]The investigators measured serum amino transferases by commercial AST kit,. ALT kits(Bayer Diagnostics,. Tarrytown, NY, USA) at six months after silymarin admission
- HCV-RNA [ Time Frame: at six months after admission ] [ Designated as safety issue: Yes ]The investigators measured serum HCV-RNA by Polymerase Chain Reaction (PCR) at six months after silymarin admission
|Study Start Date:||March 2006|
|Study Completion Date:||September 2006|
|Primary Completion Date:||September 2006 (Final data collection date for primary outcome measure)|
Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
Tab 210 mg, 630 mg, daily, six months.
Silymarin has been claimed to have a beneficial effect in various types of liver injury, including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and chronic viral hepatitis.
|Iran, Islamic Republic of|
|Al-zahra university hospital|
|Isfahan, Iran, Islamic Republic of|
|Principal Investigator:||hamid kalantari, A.Professor||Associate Professor,Gasteroentrology department|